MX351881B - Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). - Google Patents
Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).Info
- Publication number
- MX351881B MX351881B MX2014010501A MX2014010501A MX351881B MX 351881 B MX351881 B MX 351881B MX 2014010501 A MX2014010501 A MX 2014010501A MX 2014010501 A MX2014010501 A MX 2014010501A MX 351881 B MX351881 B MX 351881B
- Authority
- MX
- Mexico
- Prior art keywords
- act
- peptides
- alpha connexin
- terminal
- gels containing
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000010970 Connexin Human genes 0.000 title abstract 2
- 108050001175 Connexin Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000499 gel Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 229940042129 topical gel Drugs 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605528P | 2012-03-01 | 2012-03-01 | |
| PCT/US2013/028727 WO2013131040A1 (en) | 2012-03-01 | 2013-03-01 | Topical gels containing alpha connexin c-terminal (act) peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010501A MX2014010501A (es) | 2015-03-09 |
| MX351881B true MX351881B (es) | 2017-11-01 |
Family
ID=49083360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010501A MX351881B (es) | 2012-03-01 | 2013-03-01 | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8846605B2 (enExample) |
| EP (1) | EP2819682B1 (enExample) |
| JP (1) | JP6185937B2 (enExample) |
| KR (1) | KR102038948B1 (enExample) |
| CN (1) | CN104271142B (enExample) |
| AU (1) | AU2013225716B2 (enExample) |
| BR (1) | BR112014021653B1 (enExample) |
| CA (1) | CA2866115C (enExample) |
| DK (1) | DK2819682T3 (enExample) |
| IL (1) | IL234380B (enExample) |
| IN (1) | IN2014DN07420A (enExample) |
| MX (1) | MX351881B (enExample) |
| NZ (1) | NZ629769A (enExample) |
| RU (1) | RU2657535C2 (enExample) |
| SG (1) | SG11201405359YA (enExample) |
| WO (1) | WO2013131040A1 (enExample) |
| ZA (1) | ZA201406373B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| RU2657535C2 (ru) | 2012-03-01 | 2018-06-14 | Ферстстринг Рисерч, Инк. | Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) |
| US11246821B2 (en) * | 2016-08-30 | 2022-02-15 | Rohm And Haas Company | Personal care composition |
| MX2019009753A (es) * | 2017-02-16 | 2019-12-18 | Firststring Res Inc | Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos. |
| EP3574892A4 (en) * | 2017-06-14 | 2020-08-12 | Bio Solution Co., Ltd. | COSMETIC COMPOSITION TO REDUCE WRINKLES OR INFLAMMATION, CONTAINING SUBSTANCE P |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| KR20210057072A (ko) * | 2018-09-12 | 2021-05-20 | 퍼스트스트링 리서치 인코포레이티드 | 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법 |
| RU2691647C1 (ru) * | 2018-11-29 | 2019-06-17 | Артем Иванович Трофименко | Средство для профилактики образования патологических кожных рубцов |
| US11751056B2 (en) * | 2020-08-31 | 2023-09-05 | Oracle International Corporation | Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns |
| CA3196342A1 (en) | 2020-10-22 | 2022-04-28 | Gautam Ghatnekar | Peptide formulations and ophthalmic uses thereof |
| WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
| CN117582401B (zh) * | 2023-12-07 | 2024-04-26 | 唐宁医药科技(济南)有限公司 | 一种糖尿病足凝胶及其制备方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3603444A1 (de) | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha |
| NZ222413A (en) | 1986-11-05 | 1991-06-25 | Ethicon Inc | Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser |
| US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| CA2080538A1 (en) * | 1991-10-21 | 1993-04-22 | Joseph V. Bondi | Lyophilized acidic fibroblast growth factor |
| US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
| FR2739621B1 (fr) | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| PT1146908E (pt) | 1999-01-27 | 2005-10-31 | David Dr Becker | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
| EP1178817A2 (en) | 1999-05-14 | 2002-02-13 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
| US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| WO2002042422A2 (en) | 2000-11-10 | 2002-05-30 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
| WO2002088370A2 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Autogene nucleic acids encoding a secretable rna polymerase |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| CN1827766B (zh) | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
| US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| AU2002321903A1 (en) | 2001-08-03 | 2003-02-24 | Arbor Vita Corporation | Molecular interactions in cells |
| CA2461542A1 (en) | 2001-10-17 | 2003-04-24 | Tudor Morley Griffith | Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| JP2003238441A (ja) | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
| WO2003096981A2 (en) | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| US7560430B2 (en) | 2003-02-14 | 2009-07-14 | Human Matrix Sciences, Llc | Elastin digest compositions and methods utilizing same |
| AU2004294824A1 (en) | 2003-12-03 | 2005-06-16 | Coda Therapeutics (Nz) Ltd | Antisense compounds targeted to connexins and methods of use thereof |
| ZA200706016B (en) * | 2004-12-21 | 2008-12-31 | Musc Found For Res Dev | Compositions and methods for promoting wound healing and tissue regeneration |
| US9408381B2 (en) | 2004-12-21 | 2016-08-09 | Musc Foundation For Research Development | Alpha Connexin c-Terminal (ACT) peptides for use in transplant |
| EP2289535B8 (en) | 2004-12-21 | 2018-08-08 | MUSC Foundation for Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| CA2612522A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
| CN101198346A (zh) * | 2005-06-17 | 2008-06-11 | 雷金纳克斯生物制药公司 | Lkktet和/或lkktnt肽组合物及方法 |
| US8128947B2 (en) * | 2005-10-11 | 2012-03-06 | Dpt Laboratories, Ltd. | Surfactant-free dispersions, compositions, and use in topical formulations |
| GB0709513D0 (en) * | 2007-05-17 | 2007-06-27 | Helperby Therapeutics Ltd | Topical formulations |
| KR20150072458A (ko) | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
| RU2521329C2 (ru) | 2006-12-11 | 2014-06-27 | Коуда Терапьютикс, Инк. | Композиции и способы лечения плохо заживающих ран |
| WO2008150929A1 (en) * | 2007-05-29 | 2008-12-11 | Manhattan Pharmaceuticals, Inc. | Topical compositions comprising a macromolecule and methods of using same |
| US20110130345A1 (en) | 2007-06-21 | 2011-06-02 | Baerbel Rohrer | Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration |
| CA2592285C (en) | 2007-06-28 | 2019-10-01 | Musc Foundation For Research Development | Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides |
| CN101970663A (zh) | 2007-12-11 | 2011-02-09 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
| JP2011506446A (ja) * | 2007-12-11 | 2011-03-03 | コーダ セラピューティクス， インコーポレイテッド | 損傷した創傷治癒組成物および治療 |
| CA2710382A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
| EP2252690A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| US20130184220A1 (en) | 2007-12-21 | 2013-07-18 | Bradford James Duft | Treatment of abnormal or excessive scars |
| CA2710375A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
| EP2234656A2 (en) | 2007-12-21 | 2010-10-06 | Coda Therapeutics, Inc. | Improved medical devices |
| CA2710387A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
| EP2237796A2 (en) | 2007-12-21 | 2010-10-13 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
| WO2009085270A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| EP2252689A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
| EP2240583A2 (en) * | 2008-01-07 | 2010-10-20 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| JP2011524345A (ja) | 2008-06-04 | 2011-09-01 | コーダ セラピューティクス， インコーポレイテッド | ギャップジャンクション調節化合物を用いる疼痛の治療 |
| EP2586436A1 (en) | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| RU2657535C2 (ru) | 2012-03-01 | 2018-06-14 | Ферстстринг Рисерч, Инк. | Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) |
-
2013
- 2013-03-01 RU RU2014139668A patent/RU2657535C2/ru active
- 2013-03-01 AU AU2013225716A patent/AU2013225716B2/en not_active Ceased
- 2013-03-01 NZ NZ629769A patent/NZ629769A/en not_active IP Right Cessation
- 2013-03-01 CN CN201380023492.XA patent/CN104271142B/zh active Active
- 2013-03-01 MX MX2014010501A patent/MX351881B/es active IP Right Grant
- 2013-03-01 JP JP2014560104A patent/JP6185937B2/ja active Active
- 2013-03-01 SG SG11201405359YA patent/SG11201405359YA/en unknown
- 2013-03-01 DK DK13755720.3T patent/DK2819682T3/en active
- 2013-03-01 BR BR112014021653-3A patent/BR112014021653B1/pt active IP Right Grant
- 2013-03-01 CA CA2866115A patent/CA2866115C/en active Active
- 2013-03-01 WO PCT/US2013/028727 patent/WO2013131040A1/en not_active Ceased
- 2013-03-01 KR KR1020147027397A patent/KR102038948B1/ko active Active
- 2013-03-01 EP EP13755720.3A patent/EP2819682B1/en active Active
- 2013-03-15 US US13/815,723 patent/US8846605B2/en active Active
-
2014
- 2014-07-25 US US14/341,406 patent/US9161984B2/en active Active
- 2014-08-29 ZA ZA2014/06373A patent/ZA201406373B/en unknown
- 2014-08-31 IL IL234380A patent/IL234380B/en active IP Right Grant
- 2014-09-03 IN IN7420DEN2014 patent/IN2014DN07420A/en unknown
-
2015
- 2015-09-09 US US14/848,916 patent/US10632173B2/en active Active
-
2020
- 2020-04-27 US US16/859,075 patent/US11524049B2/en active Active
-
2022
- 2022-10-06 US US17/938,624 patent/US12128086B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014010501A (es) | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| MX378856B (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| MY161773A (en) | Amylin analogues and pharmaceutical compositions thereof | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| MY171146A (en) | Compositions of glp-1 peptides and preparation thereof | |
| PH12014500923A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| MX385591B (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX388822B (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| CY1119036T1 (el) | Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους | |
| CO2018012258A2 (es) | Compuestos de mic-1 y usos de estos | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| IN2014DN03213A (enExample) | ||
| IN2014DN06920A (enExample) | ||
| GEP201606514B (en) | Apoptosis inhibitors and usage thereof | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
| ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| TN2013000386A1 (en) | Suspension type topical formulations comprising cyclic depsipeptide | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| WO2015057820A3 (en) | Peptide constructs and well-defined aggregates thereof | |
| MX2013003545A (es) | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica. | |
| WO2016195194A3 (ko) | 신규한 tlr2 길항제 | |
| GB201018125D0 (en) | Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |